News
The FDA has rejected vatiquinone, requesting that PTC run an additional study to prove the drug's efficacy prior to ...
FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another ...
The FDA approved Sephience - PTC's oral therapy for a rare metabolic disorder called phenylketonuria - last month, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback